# Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

> **NCT06223711** · PHASE2 · RECRUITING · sponsor: **Universität des Saarlandes** · enrollment: 43 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **RADIATION:** Thoracic Radiochemotherapy
- **DRUG:** durvalumab
- **RADIATION:** Stereotactic radiotherapy of further tumor locations
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06223711
- **Lead sponsor:** Universität des Saarlandes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-06
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223711, "Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06223711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*